PMID- 9021436
OWN - NLM
STAT- MEDLINE
DCOM- 19970528
LR  - 20131121
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 35
IP  - 1
DP  - 1997 Jan
TI  - Urinary 6 beta-hydroxycortisol and D-glucaric acid excretion rates are not 
      affected by lansoprazole treatment.
PG  - 14-8
AB  - Lansoprazole has been shown to induce cytochrome P450 1A (CYP1A) and CYP3A 
      enzymes in human hepatocytes in vitro. In this study, urinary excretion of 6 
      beta-hydroxycortisol (6 beta-OHF) and D-glucaric acid (D-GA) were used to 
      investigate the potential enzyme-inducing property of lansoprazole in vivo. 
      Twenty-four healthy female volunteers (aged 19-35 years), who were taking oral 
      contraceptives containing 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel, 
      were randomized in a cross-over design for the treatment with either 60 mg 
      lansoprazole or placebo once daily during 2 subsequent menstrual cycles. Urinary 
      excretion rates of 6 beta-OHF and D-GA were measured at days 14 and 21 of the 
      menstrual cycles. Median pretreatment urinary excretion of 6 beta-OHF (212 and 
      218 micrograms/d, n = 24) and D-GA (20.1 and 32.7 mumol/d) did not significantly 
      differ. Upon treatment median excretion of 6 beta-OHF was 255 and 241 
      micrograms/d (n = 23), and that of D-GA was 25.5 and 33.8 mumol/d, respectively. 
      Thus, the relatively high dose of 60 mg/d lansoprazole failed to statistically 
      significantly alter urinary excretion of 6 beta-OHF and D-GA, indicating that 
      therapeutic doses of lansoprazole might not exhibit a phenobarbital-like 
      induction in vivo.
FAU - Rost, K L
AU  - Rost KL
AD  - Institute of Clinical Pharmacology, Universitatsklinikum Benjamin Franklin, Free 
      University of Berlin, Germany.
FAU - Mansmann, U
AU  - Mansmann U
FAU - Roots, I
AU  - Roots I
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Contraceptives, Oral, Combined)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Estradiol Congeners)
RN  - 0 (Placebos)
RN  - 0 (Progesterone Congeners)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - 53-35-0 (6 beta-hydroxycortisol)
RN  - 5W7SIA7YZW (Levonorgestrel)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - KG60484QX9 (Omeprazole)
RN  - QLZ991V4A2 (Glucaric Acid)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Adult
MH  - Contraceptives, Oral, Combined/pharmacology
MH  - Cross-Over Studies
MH  - Cytochrome P-450 Enzyme System/biosynthesis
MH  - Drug Interactions
MH  - Enzyme Induction
MH  - Enzyme Inhibitors/*pharmacology
MH  - Estradiol Congeners/pharmacology
MH  - Ethinyl Estradiol/pharmacology
MH  - Female
MH  - Glucaric Acid/*urine
MH  - Humans
MH  - Hydrocortisone/*analogs & derivatives/urine
MH  - Lansoprazole
MH  - Levonorgestrel/pharmacology
MH  - Omeprazole/*analogs & derivatives/pharmacology
MH  - Placebos
MH  - Progesterone Congeners/pharmacology
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 1997 Jan;35(1):14-8.